UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

Thrombophilia in Klinefelter Syndrome With Deep Venous Thrombosis, Pulmonary Embolism, and Mesenteric Artery Thrombosis on Testosterone Therapy: A Pilot Study

Clinical and applied thrombosis/hemostasis, 2017-11, Vol.23 (8), p.973-979

2017

Link zum Volltext

Verfügbarkeit prüfen

ADDISON'S DISEASE CAUSING PERICARDITIS WITH TAMPONADE

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.2430-2430

2021

Link zum Volltext

Verfügbarkeit prüfen

A Rare Case of Addison’s Disease Presenting With Intermittent Pancytopenia and Cardiac Tamponade

AACE clinical case reports, 2021-11, Vol.7 (6), p.353-356

2021

Link zum Volltext

Verfügbarkeit prüfen

Progressively Worsening Premature Coronary Artery Disease: Adding Anticoagulation Stabilizes–Reverses Clinical Symptomatic Disease Progression in Thrombophilic–Atherothrombotic Patients: A Pilot Study

Clinical and applied thrombosis/hemostasis, 2017-11, Vol.23 (8), p.1060-1070

2017

Link zum Volltext

Verfügbarkeit prüfen

Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant

JIM - high impact case reports, 2016-07, Vol.4 (3), p.2324709616661833-2324709616661833

2016

Link zum Volltext

Verfügbarkeit prüfen

Eligibility for Alirocumab or Evolocumab Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With LDL Cholesterol ≥70 Mg/Dl Despite Maximal Tolerated Cholesterol Lowering Therapy

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.786-786

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, Safety, LDL Cholesterol Lowering, and 10-Year ASCVD Risk Reduction: Alirocumab and Evolocumab in Addition to Maximal Tolerated LDL Lowering

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.802-802

2017

Link zum Volltext

Verfügbarkeit prüfen

Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia

BMC blood disorders, 2016-03, Vol.16 (6), p.6-6, Article 6

2016

Link zum Volltext

Verfügbarkeit prüfen

THE HEROIN EPIDEMIC FORBODES THE ACQUIRED GERBODE DEFECT

Journal of the American College of Cardiology, 2019-03, Vol.73 (9), p.2630-2630

2019

Link zum Volltext

Verfügbarkeit prüfen

ATHEROMA HIGHLIGHTS THE IMPORTANCE OF CONTINUED TRANSESOPHAGEAL ECHOCARDIOGRAPHIC GUIDANCE DURING TRANSCATHETER AORTIC VALVE REPLACEMENT

Journal of the American College of Cardiology, 2021-05, Vol.77 (18), p.2647-2647

2021

Link zum Volltext

Verfügbarkeit prüfen

LEFT VENTRICULAR FREE WALL RUPTURE CONTAINED BY POST-OPERATIVE INTRAPERICARDIAL ADHESIONS FROM PREVIOUS CORONARY ARTERY BYPASS SURGERY

Journal of the American College of Cardiology, 2020-03, Vol.75 (11), p.3215-3215

2020

Link zum Volltext

Verfügbarkeit prüfen

Right-sided approach for left bundle branch area pacing is feasible and successful

Heart rhythm, 2024-03, Vol.21 (3), p.352-354

2024

Link zum Volltext

Verfügbarkeit prüfen

PO-03-042 FIRST EXPERIENCE WITH THE 2088TC-38 LEAD FOR CONDUCTION SYSTEM PACING USING THE ABBOTT CPS LOCATOR 3D DELIVERY SYSTEM: A NEW KID ON THE BLOCK?

Heart rhythm, 2024-05, Vol.21 (5), p.S358-S359

2024

Link zum Volltext

Verfügbarkeit prüfen

ATYPICAL PRESENTATION OF CONGENITIAL ADRENAL HYPERPLASIA

Endocrine practice, 2018-04, Vol.24, p.1-1

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract #100 Atypical Presentation of Congenitial Adrenal Hyperplasia

Endocrine practice, 2018-04, Vol.24, p.1

2018

Link zum Volltext

Verfügbarkeit prüfen

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol [greater than or equal to]70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.(ORIGINAL RESEARCH)

Vascular health and risk management, 2020-03, p.247

2020

Link zum Volltext

Verfügbarkeit prüfen

SEVERE REPERCUSSIONS OF ROUX-EN-Y SURGERY

Endocrine practice, 2018-04, Vol.24, p.105-105

2018

Link zum Volltext

Verfügbarkeit prüfen

Abstract #500 Severe Repercussions of Roux-En-Y Surgery

Endocrine practice, 2018-04, Vol.24, p.105

2018

Link zum Volltext

Verfügbarkeit prüfen

Venous Thromboembolism After Knee Arthroscopy in Undiagnosed Familial Thrombophilia

Orthopedics (Thorofare, N.J.), 2016-11, Vol.39 (6), p.e1052

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

Lipids in health and disease, 2016-08, Vol.15 (1), p.132-132, Article 132

2016

Link zum Volltext

Verfügbarkeit prüfen

CRT-800.02 Eligibility for PCSK9 Treatment in 734 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With Heterozygous Familial Hypercholesterolemia With LDL Cholesterol >100 Mg/dl and/or Atherosclerotic Cardiovascular Disease With LDL Cholesterol >70 Mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

JACC. Cardiovascular interventions, 2016-02, Vol.9 (4), p.S61-S62

2016

Link zum Volltext

Verfügbarkeit prüfen

Associations between serum 25-hydroxyvitamin D and lipids, lipoprotein cholesterols, and homocysteine

North American journal of medical sciences, 2016-07, Vol.8 (7), p.284-290

2016

Link zum Volltext

Verfügbarkeit prüfen

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy

Lipids in health and disease, 2016-03, Vol.15 (55), p.55-55, Article 55

2016

Link zum Volltext

Verfügbarkeit prüfen

Safety of 50,000-100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance

North American journal of medical sciences, 2016-03, Vol.8 (3), p.156-162

2016

Link zum Volltext

Verfügbarkeit prüfen

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

Vascular health and risk management, 2017-01, Vol.13, p.247-253

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(26)

Publikationsform

Artikel
(26)
Berichte
(1)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Care And Treatment
(6)
Humans
(6)
Female
(5)
Hypercholesterolemia
(5)
Male
(5)
Middle Aged
(5)
Anticoagulants
(4)
Cardiovascular Disease
(4)
Cardiovascular System & Cardiology
(4)
Complications And Side Effects
(4)
Health Aspects
(4)
Mutation
(4)
Thrombophilia
(4)
Adult
(3)
Aged
(3)
Antibodies, Monoclonal - Therapeutic Use
(3)
Anticholesteremic Agents - Therapeutic Use
(3)
Cardiovascular
(3)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Thrombophilia in Klinefelter Syndrome With Deep Venous Thrombosis, Pulmonary Embolism, and Mesenteric Artery Thrombosis on Testosterone Therapy: A Pilot Study

ADDISON'S DISEASE CAUSING PERICARDITIS WITH TAMPONADE

A Rare Case of Addison’s Disease Presenting With Intermittent Pancytopenia and Cardiac Tamponade

Progressively Worsening Premature Coronary Artery Disease: Adding Anticoagulation Stabilizes–Reverses Clinical Symptomatic Disease Progression in Thrombophilic–Atherothrombotic Patients: A Pilot Study

Four Thrombotic Events Over 5 Years, Two Pulmonary Emboli and Two Deep Venous Thrombosis, When Testosterone-HCG Therapy Was Continued Despite Concurrent Anticoagulation in a 55-Year-Old Man With Lupus Anticoagulant

Eligibility for Alirocumab or Evolocumab Treatment in 1090 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With LDL Cholesterol ≥70 Mg/Dl Despite Maximal Tolerated Cholesterol Lowering Therapy

Efficacy, Safety, LDL Cholesterol Lowering, and 10-Year ASCVD Risk Reduction: Alirocumab and Evolocumab in Addition to Maximal Tolerated LDL Lowering

Hospitalization for pulmonary embolism associated with antecedent testosterone or estrogen therapy in patients found to have familial and acquired thrombophilia

THE HEROIN EPIDEMIC FORBODES THE ACQUIRED GERBODE DEFECT

ATHEROMA HIGHLIGHTS THE IMPORTANCE OF CONTINUED TRANSESOPHAGEAL ECHOCARDIOGRAPHIC GUIDANCE DURING TRANSCATHETER AORTIC VALVE REPLACEMENT

LEFT VENTRICULAR FREE WALL RUPTURE CONTAINED BY POST-OPERATIVE INTRAPERICARDIAL ADHESIONS FROM PREVIOUS CORONARY ARTERY BYPASS SURGERY

Right-sided approach for left bundle branch area pacing is feasible and successful

PO-03-042 FIRST EXPERIENCE WITH THE 2088TC-38 LEAD FOR CONDUCTION SYSTEM PACING USING THE ABBOTT CPS LOCATOR 3D DELIVERY SYSTEM: A NEW KID ON THE BLOCK?

ATYPICAL PRESENTATION OF CONGENITIAL ADRENAL HYPERPLASIA

Abstract #100 Atypical Presentation of Congenitial Adrenal Hyperplasia

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol [greater than or equal to]70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy.(ORIGINAL RESEARCH)

SEVERE REPERCUSSIONS OF ROUX-EN-Y SURGERY

Abstract #500 Severe Repercussions of Roux-En-Y Surgery

Venous Thromboembolism After Knee Arthroscopy in Undiagnosed Familial Thrombophilia

Pharmacoeconomics of PCSK9 inhibitors in 103 hypercholesterolemic patients referred for diagnosis and treatment to a cholesterol treatment center

Associations between serum 25-hydroxyvitamin D and lipids, lipoprotein cholesterols, and homocysteine

Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy

Safety of 50,000-100,000 units of vitamin D3/week in vitamin D-deficient, hypercholesterolemic patients with reversible statin intolerance

Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg/dL despite maximal-tolerated LDL-cholesterol-lowering therapy

Suchergebnisse filtern